Publications by authors named "P Jimenez-Labaig"
Article Synopsis
- Patients with head and neck cancer (HNC) often experience significant mental health challenges, particularly depressive and anxiety symptoms, especially during and after radiotherapy (RT).
- A systematic review of 18 studies with nearly 2,000 participants revealed a peak in depressive symptoms shortly after RT, with rates decreasing over time, while anxiety symptoms showed a continuous decline.
- Demographics indicated that female and married patients had higher levels of depression, while those who had surgery reported fewer anxiety symptoms; highlighting the need for mental health support during the RT process.
Background: Directly-injected therapies (DIT) include a broad range of agents within a developing research field in cancer immunotherapy, with encouraging clinical trial results in various tumour subtypes. Currently, the majority of such therapies are only available within clinical trials; however, more recently, talimogene laherparepvec (T-VEC, Imlygic) has been approved as the first oncolytic virus therapy in the USA and Europe. Our institution contributes to multiple different trials exploring the efficacy of DIT, the majority of which are performed by oncologists in clinic.
View Article and Find Full Text PDFSalivary gland cancers (SGC) are rare tumours with limited availability of systemic therapies. Some SGC subtypes overexpress HER2, and this represents a potential therapeutic target, but the evidence base is limited. This study sought to analyse real-world data on the efficacy of HER2-directed therapies in SGC.
View Article and Find Full Text PDFIntroduction: There is a need to improve the outcomes of patients with head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC), especially in recurrent unresectable and metastatic (R/M) setting. Antibody-drug conjugates (ADC) and bispecific antibodies (BsAb) may deliver promising results.
Methods: We conducted a systematic literature review to identify ADC and BsAb clinical trials, involving patients with HNSCC and NPC, from database creation to December 2023.